The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...